Shandong Xinhua Pharmaceutical Company Limited (00719.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

4.8x

EV/EBITDA

9.3x

Market Cap

HKD 3.94B

MomentumView details →

1D Return

+0.53%

YTD Return

−14.26%

RSI (14)

37.4

ValuationView details →

P/E (Fwd)

4.8x

EV/EBITDA

9.3x

Market Cap

HKD 3.94B

RSI (14)

37.4

MomentumView details →

1D Return

+0.53%

YTD Return

−14.26%

ProfitabilityView details →

Gross Margin

17.79%

Net Margin

2.54%

EBITDA Margin

5.19%

ROE (TTM)

4.07%

ROA (TTM)

2.35%

Asset Turnover

0.93x

GrowthView details →

Revenue YoY

+0.75%

EPS YoY

−48.27%

FCF YoY

+148.67%

Revenue CAGR 3Y

+5.28%

EPS CAGR 3Y

−12.17%

EBITDA YoY

−18.55%

EarningsView details →

EPS (Actual)

HKD 0.20

EPS Surprise

0.00%

Beats (12Q)

0/12

Next Q EPS Est

HKD 0.32

Avg Surprise (4Q)

0.00%

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.37x

Current Ratio

1.54x

Quick Ratio

1.07x

Div Yield

3.05%

Div Rate

HKD 0.17

Div Growth 1Y

−36.85%

Financials snapshotView financials →

Revenue (TTM)

8.44B

Net Income (TTM)

214.48M

Op. CF (TTM)

466.13M

Next earningsOct 23, 2026 →

Latest newsMore news →

Xinhua Pharmaceutical's wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical received approval for its azithromycin tablets 0.25g to pass generic drug consistency evaluation, enabling market entry.5d ago

Xinhua Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its dapoxetine hydrochloride tablets, a 30mg Class 4 chemical prescription drug for treating premature ejaculation in men aged 18-64, approved in August 2026.8d ago

Similar companies

卫信康603676.SH 灵康药业603669.SH 司太立603520.SH Indivior Pharmaceuticals IncINDV 太龙药业600222.SH 健民集团600976.SH Find similar companies →

Latest newsMore news →

Xinhua Pharmaceutical's wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical received approval for its azithromycin tablets 0.25g to pass generic drug consistency evaluation, enabling market entry.5d ago Xinhua Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its dapoxetine hydrochloride tablets, a 30mg Class 4 chemical prescription drug for treating premature ejaculation in men aged 18-64, approved in August 2026.8d ago